Valeant Pharmaceuticals International (VRX) Posts Q1 EPS of $0.02, Tops Revenue Expectations and Raises FY11 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts VRX Hot Sheet
Price: $23.40 --0%
Financial Fact:
Less: Net income attributable to noncontrolling interest: 1K
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Less: Net income attributable to noncontrolling interest: 1K
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) reported Q1 EPS of $0.02, versus ($0.02) reported last year. Revenue for the quarter came in at $565 million versus the consensus estimate of $297.08 million.
Valeant Pharmaceuticals International, Inc. raised it FY2011 EPS guidance to $2.65-$2.90 from $2.45-$2.70.
Valeant Pharmaceuticals International, Inc. raised it FY2011 EPS guidance to $2.65-$2.90 from $2.45-$2.70.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
- First Citizens Bancshares (FCNCA) reported Q3 EPS
- Rithm Capital Corp. (RITM) Tops Q3 EPS by 6c
Create E-mail Alert Related Categories
Earnings, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
